Generic Substitution of Lamotrigine Among Medicaid Patients with Diverse Indications
Open Access
- 1 August 2012
- journal article
- Published by Springer Science and Business Media LLC in CNS Drugs
- Vol. 26 (8), 707-716
- https://doi.org/10.2165/11634260-000000000-00000
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- The backlash against bioequivalence and the interchangeability of brand-name and generic drugsCMAJ : Canadian Medical Association Journal, 2011
- Switching from Brand‐Name to Generic Psychotropic Medications: A Literature ReviewCNS Neuroscience & Therapeutics, 2010
- Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug AdministrationAnnals of Pharmacotherapy, 2009
- Effects of Antiepileptic Drug Substitutions on Epileptic Events Requiring Acute CarePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- The risks and costs of multiple-generic substitution of topiramateNeurology, 2009
- Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian settingCurrent Medical Research and Opinion, 2008
- What’s the problem with generic antiepileptic drugs?Neurology, 2007
- An epidemiological investigation of off‐label anticonvulsant drug use in the Georgia Medicaid populationPharmacoepidemiology and Drug Safety, 2005
- Bioequivalence and other unresolved issues in generic drug substitutionClinical Therapeutics, 2003
- The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute EventsAmerican Journal of Epidemiology, 1991